
    
      In this prospective, single center, randomized, active-controlled, observer-blind, Phase 3
      descriptive study, 660 healthy Gambian pneumococcal conjugate vaccine (PCV)-na√Øve infants
      will be randomized 1:1:1 to receive 3 doses of either PNEUMOSIL, Synflorix or Prevenar 13 at
      6 weeks, 14 weeks and 9 months of age. Standard EPI vaccinations in The Gambia, will be given
      concomitantly with all 3 doses of study vaccine.Blood will be collected 4 weeks post second
      dose, pre-booster and 4 weeks post booster dose for immunogenicity assessments.
    
  